- Policy
- Amgen starts negotiations to extend reimb of Kyprolis
- by Lee, Tak-Sun Oct 15, 2024 05:50am
- The reimbursement extension process for the multiple myeloma drug Kyprolis (carfilzomib, Amgen) has entered the final stage. Its insurance drug price is being negotiated with the National Health Insurance Service. The discussion is likely for the use of Kyprolis in the Kyprolis+daratumumab+dexamethasone (DKd) regimen, which passed the Can
- Policy
- Reduced reimb for medicines-containing choline alfoscerate
- by Lee, Tak-Sun Oct 15, 2024 05:49am
- Complaints have been circulating regarding the decision made by the Health Insurance Review and Assessment Service (HIRA) to reduce reimbursement on medical care reimbursement claims for medicines containing 'choline alfoscerate,' a brain function-improving agent. Medicines-containing choline alfoscerate received selective reimbursement
- Policy
- Will generics dominate the oral psoriasis treatment market?
- by Lee, Tak-Sun Oct 14, 2024 05:49am
- The global market for oral psoriasis treatment amounts to KRW 5 trillion. In the Korean market, generic medicines are likely to dominate. The original medicine company withdrew its drug from the Korean market due to dissatisfaction with the reimbursement decision, whereas generic medicines are likely to accept the term. A new type of oral
- Policy
- NA-MFDS clash on the approval of abortion pills
- by Lee, Jeong-Hwan Oct 14, 2024 05:49am
- With the National Assembly strongly pressing the need for domestic marketing authorization of the abortion drug ‘Mifegymiso,’ the NA’s request is set to affect the future administration of the MFDS’s marketing authorization review. The MFDS has repeatedly argued that the Criminal Act and the Mother and Child Health Act must be amen
- Policy
- Approval process for 'Leqembi' heavily debated
- by Lee, Hye-Kyung Oct 14, 2024 05:49am
- A heated debate is expected during the National Assembly regarding the approval process for Leqembi (lecanemab), a new drug for treating dementia that received domestic approval in May. At a parliamentary audit of the Health and Welfare Committee held at the National Assembly on October 10th, Rep. Jeon Jin-sook, a member of the Democratic
- Policy
- Drug pricing negotiations for Qarziba gather pace
- by Lee, Tak-Sun Oct 14, 2024 05:49am
- With Qarziba Inj (dinutuximab beta, Recordati Korea), the first drug that has been applied the approval-evaluation-negotiation pilot project, passing the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee, the drug price negotiation for the drug is also expected to progress quickly. However, the drug
- Policy
- MFDS Minister ‘will work with MOHW on INN prescriptions’
- by Lee, Hye-Kyung Oct 11, 2024 05:54am
- International non-proprietary names (INNs) and ingredient-based prescriptions should be introduced to prevent patients from circling pharmacies due to drug shortages, said a lawmaker. ‘Institutional inducements such as the introduction of INNs and ingredient-name prescriptions are needed to prevent drug supply disruptions and pharmacy bounci
- Policy
- "Preferential drug pricing excludes K-made new drug benefits
- by Lee, Jeong-Hwan Oct 10, 2024 05:50am
- The government's revised plan for the drug pricing system has been criticized for reverse discrimination against Korean pharmaceutical companies because it was primarily designed to favor multinational pharmaceutical companies. The criticism concerns the revised drug pricing system plan, announced by the Health Insurance Review and Assessment
- Policy
- Yoon Kim ‘40% of the generic drug price is a bubble’
- by Lee, Jeong-Hwan Oct 10, 2024 05:50am
- Kyoo-hong Cho, the Minister of Health and Welfare, positively responded to Democratic Party of Korea Representative Yoon Kim's request to lower the price of generic versions of patent-expired drugs within the year. This refers to a separate generic drug price cut rather than the foreign drug price referencing reevaluations, which the phar
- Policy
- Daewoong wins nod for first generic version of Ibrance tab
- by Lee, Tak-Sun Oct 8, 2024 05:49am
- Daewoong's first generic for Pfizer's breast cancer treatment, 'Ibrance Tab,' has been approved. Due to the successful patent nullification, the company received priority marketing authorization. The first generic can be launched in March 23rd, 2027, when the product patent expires. The Ministry of Food and Drug Safety (MFDS) has granted
